PNFS
ELDN icon

PW Nova Financial Services’s Eledon Pharmaceuticals ELDN Stock Holding History

PW Nova Financial Services’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Hold
58,041
– – 0.05% 191
2026
Q1 		$179K Hold
58,041
– – 0.04% 188
2025
Q4 		$94K Buy
+58,041
New +$138K 0.04% 110

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

PW Nova Financial Services's ELDN Position: Q2 2026 in Review

PW Nova Financial Services held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 58,041 shares worth $229K. The position accounts for 0.05% of the portfolio, ranked #191.

PW Nova Financial Services first reported a position in ELDN in Q4 2025 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • PW Nova Financial Services held 58,041 shares of Eledon Pharmaceuticals worth $229K as of Q2 2026.
  • PW Nova Financial Services left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up 0.05% of PW Nova Financial Services's portfolio in Q2 2026, its #191 holding.
  • PW Nova Financial Services first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on PW Nova Financial Services's 13F filing for Q2 2026, filed 29 Jul 2026.